서울대학교 중앙도서관

S-Space 소개

My S-Space

로그인이 필요합니다.

Login

S-Space

Browse

Author

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 1 to 4 of 4

Issue Date	Title / Author(s) / Citation	File	Altmetrics
2018-11	Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer Camidge, D. Ross; Kim, Hye Ryun; Ahn, Myung-Ju; Yang, James Chih-Hsin -H.; Han, Ji-Youn; Lee, Jong-Seok; Hochmair, Maximilian J.; Li, Jacky Yu-Chung; Chang, Gee-Chen; Lee, Ki Hyeong; Gridelli, Cesare; Delmonte, Angelo; Garcia Campelo, Rosario; Kim, Dong-Wan; Bearz, Alessandra; Griesinger, Ffrank; Morabito, Alessandro; Felip, Enriqueta; Califano, Raffaele; Ghosh, Sharmistha; Spira, Alexander; Gettinger, Scott N.; Tiseo, Marcello; Gupta, Neeraj; Haney, Jeff; Kerstein, David; Popat, Sanjay New England Journal of Medicine, Vol.379 No.21, pp.2027-2039	DOI
2020-11	Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial Camidge, D. Ross; Kim, Hye Ryun; Ahn, Myung-Ju; Yang, James C. H.; Han, Ji-Youn; Hochmair, Maximilian J.; Lee, Ki Hyeong; Delmonte, Angelo; Garcia Campelo, Maria Rosario; Kim, Dong-Wan; Griesinger, Frank; Felip, Enriqueta; Califano, Raffaele; Spira, Alexander; Gettinger, Scott N.; Tiseo, Marcello; Lin, Huamao M.; Gupta, Neeraj; Hanley, Michael J.; Ni, Quanhong; Zhang, Pingkuan; Popat, Sanjay Journal of Clinical Oncology, Vol.38 No.31, pp.3592-3603	DOI
2021-12	Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial Camidge, D. Ross; Kim, Hye Ryun; Ahn, Myung-Ju; Yang, James C. H.; Han, Ji-Youn; Hochmair, Maximilian J.; Lee, Ki Hyeong; Delmonte, Angelo; Campelo, D. h Maria Rosario Garcia; Kim, Dong-Wan; Griesinger, Frank; Felip, Enriqueta; Califano, Raffaele; Spira, Alexander I.; Gettinger, Scott N.; Tiseo, Marcello; Lin, Huamao M.; Liu, Yuyin; Vranceanu, Florin; Niu, Huifeng; Zhang, Pingkuan; Popat, Sanjay Journal of Thoracic Oncology, Vol.16 No.12, pp.2091-2108	DOI
2022-12	Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK plus Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study Ahn, Myung J.; Kim, Hye R.; Yang, James C. H.; Han, Ji-Yu; Li, Jacky Yu-Chung; Hochmair, Maximilian J.; Chang, Gee-Chen; Delmonte, Angelo; Lee, Ki H.; Campelo, Rosario G.; Gridelli, Cesare; Spira, Alexander, I; Califano, Raffaele; Griesinger, Frank; Ghosh, Sharmistha; Felip, Enriqueta; Kim, Dong-Wan; Liu, Yuyin; Zhang, Pingkuan; Popat, Sanjay; Camidge, D. Ross Clinical Lung Cancer, Vol.23 No.8, pp.720-730	DOI

1